Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin
- Yue-Jin Huang1Email author,
- Paul M Lundy2,
- Anthoula Lazaris1, 4,
- Yue Huang1,
- Hernan Baldassarre1,
- Bin Wang1, 5,
- Carl Turcotte1,
- Mélanie Côté1,
- Annie Bellemare1,
- Annie S Bilodeau1,
- Sandra Brouillard1,
- Madjid Touati1,
- Peter Herskovits1,
- Isabelle Bégin1,
- Nathalie Neveu1,
- Eric Brochu1,
- Janice Pierson1,
- Duncan K Hockley1,
- Douglas M Cerasoli3,
- David E Lenz3,
- Harvey Wilgus1,
- Costas N Karatzas1, 6 and
- Solomon Langermann1
© Huang et al; licensee BioMed Central Ltd. 2008
Received: 18 December 2007
Accepted: 16 May 2008
Published: 16 May 2008
Human butyrylcholinesterase (huBChE) has been shown to be an effective antidote against multiple LD50 of organophosphorus compounds. A prerequisite for such use of huBChE is a prolonged circulatory half-life. This study was undertaken to produce recombinant huBChE fused to human serum albumin (hSA) and characterize the fusion protein.
Secretion level of the fusion protein produced in vitro in BHK cells was ~30 mg/liter. Transgenic mice and goats generated with the fusion constructs expressed in their milk a bioactive protein at concentrations of 0.04–1.1 g/liter. BChE activity gel staining and a size exclusion chromatography (SEC)-HPLC revealed that the fusion protein consisted of predominant dimers and some monomers. The protein was confirmed to have expected molecular mass of ~150 kDa by Western blot. The purified fusion protein produced in vitro was injected intravenously into juvenile pigs for pharmacokinetic study. Analysis of a series of blood samples using the Ellman assay revealed a substantial enhancement of the plasma half-life of the fusion protein (~32 h) when compared with a transgenically produced huBChE preparation containing >70% tetramer (~3 h). In vitro nerve agent binding and inhibition experiments indicated that the fusion protein in the milk of transgenic mice had similar inhibition characteristics compared to human plasma BChE against the nerve agents tested.
Both the pharmacokinetic study and the in vitro nerve agent binding and inhibition assay suggested that a fusion protein retaining both properties of huBChE and hSA is produced in vitro and in vivo. The production of the fusion protein in the milk of transgenic goats provided further evidence that sufficient quantities of BChE/hSA can be produced to serve as a cost-effective and reliable source of BChE for prophylaxis and post-exposure treatment.
Poisoning with organophosphorus (OP) compounds is a severe problem facing military personnel who may encounter lethal doses of these compounds in chemical warfare situations. Further, OP and other anticholinesterase agents are extensively used as pesticides and pose a substantial occupational and environmental risk. Human serum butyrylcholinesterase (huBChE, EC 220.127.116.11) is a globular, tetrameric molecule with a molecular mass of ~340 kDa . Administration of exogenous huBChE has been shown to be an effective and safe alternative treatment for the prevention of OP nerve agent toxicity [2–7], although the physiological function of huBChE is largely elusive. In addition, it can hydrolyze many ester-containing drugs such as cocaine and succinylcholine . Of the cholinesterases evaluated for nerve agent scavenging potential so far, huBChE purified from plasma has a relatively long half-life , a broad spectrum of activity against a variety of nerve agents including sarin, soman, tabun and VX, and limited, if any, physiological side effects . However, huBChE may not be a viable option because it is only expressed at ~5 mg/liter in human plasma  and production of large quantities needed for civilian and military stockpiles is impractical. Recombinant huBChE has been expressed in bacteria  and in mammalian cell lines [12, 13]. However, these recombinant production strategies have not yet produced sufficient quantities of functional BChE with a residence time similar to native huBChE to allow the economically reasonable development of recombinant enzyme as a prophylactic indication against OP poisoning. Recently it has been shown that large quantities of recombinant huBChE can be produced in the milk of transgenic goats for prophylaxis of humans at risk for exposure to OP nerve agents [14, 15]. One way to achieve plasma stability and longer half-life of recombinant BChE while maintaining its biological activity is to provide a recombinantly produced BChE fused to human serum albumin (hSA).
It is well known that hSA, the most abundant protein in plasma, is a good carrier protein with a substantial circulatory half-life (up to 19 days in the human blood) and is widely distributed in vivo . A number of proteins have been fused to albumin to improve their circulating half-lives and stability characteristics [17–19]. It has been reported that some therapeutic proteins genetically fused with hSA in general have longer circulating half-lives and improved pharmacokinetic and pharmacodynamic profiles compared to the non-fused proteins. Further, hSA has been shown to covalently bind OP agents in vitro [20, 21] and in vivo, and therefore OP bound to hSA may serve as a biomarker of OP exposure in humans . We hypothesized that it might be possible to delay the clearance of a rapidly cleared recombinant BChE via fusion to this slowly cleared plasma protein. This fusion protein may exhibit high plasma stability in the body and is expected to be either weakly or non-immunogenic for the organism in which it is used . In addition, an affinity column, for example, an Affi-Gel Blue Gel column, can be used as an additional purification procedure for the hSA fused protein. Therefore, a series of DNA expression constructs harboring the sequence encoding the mature hSA fused in frame to the 3' end of the huBChE cDNA sequence with a DNA sequence encoding a (Gly)6-Ser amino acid linker were made. The fusion protein was produced first in vitro in BHK cells and used in a pharmacokinetic study as a proof-of-concept experiment, followed by fast generation of transgenic mice. Milk samples containing the fusion protein from a transgenic mouse were tested against a variety of nerve agents. Further, transgenic goats were generated for large-scale production of the fusion protein.
Construction of in vitro DNA expression vector CMV/BChE/hSA
Standard recombinant DNA methods employed herein have been described in detail . All DNA cloning manipulations were performed using Escherichia coli Stbl2™ competent cells (Invitrogen, Burlington, ON, Canada). Restriction and modifying enzymes were purchased from New England BioLabs (Ipswich, MA). All chemicals used were reagent grade and purchased from Sigma-Aldrich (Oakville, ON, Canada), unless otherwise specified. Construct integrity was verified using DNA sequencing service provided by Mobix Lab (McMaster University, ON, Canada). Primers for sequencing and PCR were synthesized by Sigma-Genosys (Oakville, ON, Canada). PCR was performed using Ready-To-Go™ PCR beads (GE Healthcare Life Sciences, Baie d'Urfe, QC, Canada) or an Expand High Fidelity PCR kit (Roche Diagnostics, Laval, QC, Canada).
The huBChE cDNA was amplified by PCR from cDNA clone ATCC #65726  (ATCC, Manassas, VA) with a sense primer Acb787 (5' AGA GAG GGG GCC CAA GAA GAT GAC ATC ATA ATT G 3') containing an ApaI site (underlined), partial Ig kappa signal sequence and an antisense primer Acb786 (5' CTG CGA GTT TAA ACT ATT AAT TAG AGA CCC ACA C 3') including a PmeI site (underlined) and partial 3' sequence of the huBChE cDNA. The PCR product was digested with ApaI and PmeI, purified using GFX matrix (GE Healthcare Life Sciences) and ligated into ApaI-PmeI digested CMV688M4 (kindly provided by Dr. J. F. Zhou, then Nexia Biotechnologies, Inc.) to generate CMV/BChE. PCR was performed using the CMV/BChE as a template with a sense primer Acb710 (5' GTG TAA CTC TCT TTG GAG AAA G 3') containing a portion of 5' BChE sequence and an antisense primer Acb853 (5' TAT AAG TTT AAA CAT ATA ATT GGA TCC TCC ACC TCC GCC TCC GAG ACC CAC ACA ACT TTC TTT CTT G 3') containing a PmeI site (underlined), a BamHI site (italic), a (Gly)6-Ser linker (bolded) followed by a portion of 3' BChE sequence. The PCR product was digested with XbaI, a restriction enzyme site located 185 bp downstream of the primer binding site of Acb710, and PmeI, and ligated to XbaI-PmeI digested CMV/BChE to generate an intermediate vector, CMV/BChEmd.
PCR was performed using Marathon-Ready™ human liver cDNA pool (Clontech, Mountain View, CA) as a template with a sense primer Acb854 (5' ATA TAA GGA TCC GAT GCA CAC AAG AGT GAG GTT GCT CAT C 3') containing a BamHI site (underlined) and partial sequence from the hSA cDNA 5' end (GenBank accession #V00495, without the signal sequence), and an antisense primer Acb855 (5' ATT TAA GTT TAA ACT CAT TAT AAG CCT AAG GCA GCT TGA CTT GC 3') including a PmeI site (underlined) and partial sequence from the hSA cDNA 3' end. This PCR product was digested with BamHI and PmeI, and inserted into BamHI-PmeI digested CMV/BChEmd to generate the final construct, CMV/BChE/hSA.
Construction of in vivo DNA expression vectors
A DNA expression vector bCN/BChE  was digested with XhoI to remove the BChE insert. The BChE-less vector was blunt-ended by filling in with Klenow polymerase in the presence of dNTPs, and calf intestine alkaline phosphatase treated. The in vitro DNA expression vector CMV/BChE/hSA (see described above) was partially digested with NcoI to remove the BChE/hSA encoding sequences. The BChE/hSA fragment was blunt-ended by filling in with Klenow polymerase in the presence of dNTPs, and PmeI digested. The two blunt-ended fragments were ligated to generate bCN/BChE/hSA for pronuclear microinjection to produce transgenic mice. PCR cloning was performed to insert a neomycin fragment between the insulators and the β-casein promoter  in bCN/BChE/hSA to generate Neo-bCN/BChE/hSA for nuclear transfer in transgenic goats. For all the in vivo DNA expression vectors, the signal sequence is either from goat β-casein or BChE itself. Linear DNA (NotI digestion), free of bacterial sequences, was prepared . DNA was quantified using a fluorometer and stored at 4°C.
Transfection and selection of stable cell lines
BHK cells were transfected with Lipofectamine PLUS Reagent (Invitrogen) as per the manufacturer's recommendations using 4 μg of the CMV/BChE/hSA DNA. Briefly, the DNA was diluted to a final volume of 750 μl with DMEM (Invitrogen) and 20 μl of PLUS Reagent was added to the mixture. The Lipofectamine was diluted to a final volume of 750 μl with DMEM. After incubation at room temperature for 15 min, the Lipofectamine and DNA mixtures were combined and complexes were allowed to form for 15 min at room temperature. The lipid-DNA complex mixture was applied to BHK cells (ATCC), and the cells were allowed to incubate for 3 h at 37°C under 5% CO2. The cells were then cultured for another 24 h in fresh medium containing 20% fetal bovine serum (Invitrogen). Subsequently, stably transfected cells were selected in DMEM containing 10% fetal bovine serum and 300 μg/ml hygromycin B (Invitrogen). Colonies surviving selection were picked 7 to 14 days following transfection and expanded further.
The level of BChE activity in cell culture media from CMV/BChE/hSA transfected BHK cells was evaluated using a commercially available kit (Sigma-Aldrich). From over 100 clones tested, the one demonstrating the highest BChE activity (Clone 35) was further evaluated in roller bottles containing serum-free DMEM. A master cell bank was generated and used to initiate a hollow fiber bioreactor (CP2500 model, Biovest International, Worcester, MA) production run. Hollow fiber production of stable transfectants was established to produce the fusion protein.
Production of founder and subsequent generation of transgenic animals
The production and maintenance of transgenic mice were conducted at the McIntyre Transgenic Core Facility of McGill University (Montreal, QC, Canada). Animal studies were carried out in accordance with Guidelines on the care and use of experimental animals from the Canadian Council of Animal Care (CCAC). Transgenic mice were generated essentially as described in  in a Friend virus B-type (FVB) background strain (Charles River Laboratories, Wilmington, MA). The bCN/BChE/hSA transgene was microinjected into the pronuclei of fertilized eggs, and 31 pups were born. At 2–3 weeks of age tail biopsies were taken, under anesthesia, and DNA was prepared according to standard procedures . Transgenic founder mice were bred with wild-type mice of the same strain for the production of F1 and F2 generations.
The production and maintenance of transgenic goats were conducted at Caprine Production Farm (CPF) of then Nexia Biotechnologies Inc. Animal studies were carried out in accordance with Guidelines on the care and use of experimental animals from CCAC. The production of the founders and subsequent generation of transgenic goats was performed by nuclear transfer as described in Keefer et al.  using the DNA expression vector, Neo-bCN/BChE/hSA.
PCR, Southern blot and FISH analysis
DNA samples from tails of mice and blood of goats were obtained 2–3 weeks and ~4 days after birth, respectively. Transgenic mice and goats were initially identified by PCR and subsequently confirmed by Southern blot analysis. PCR was performed by employing three sets of primers for each sample. Set A (Acb852, 5' CTT CCG TGG CCA GAA TGG ATG GGA GTG 3'/Acb883, 5' AAG AAA AGG AGT TCC GGG GC 3') amplified a 930 bp fragment from the 3' end of the BChE cDNA and hSA cDNA 5' end. Set B (Acb268, 5'AGG AGC ACA GTG CTC ATC CAG ATC 3'/Acb659, 5' GAC GCC CCA TCC TCA CTG ACT 3') amplified a 910 bp fragment of the insulator sequence. Set C for mice (Acb572, 5' TTC CTA GGA TGT GCT CCA GGC T 3'/Acb255, 5' GAA ACG GAA TGT TGT GGA GTG G 3') or goat (Acb256, 5' GAG GAA CAA CAG CAA ACA GAG 3'/Acb312, 5' ACC CTA CTG TCT TTC ATC AGC 3') amplified a 500 bp or a 360 bp portion of an endogenous mouse or goat β-casein gene, respectively, and ensured that the extracted DNA contained no inhibitors for the PCR reaction and it could therefore be amplified. Upon amplification the DNA samples were electrophoresed on a 1% agarose gel. Confirmation of intactness and copy number of the transgene was assessed with Southern blot analysis  using the DIG system (Roche Diagnostics). The transgene integration sites in the transgenic goats were investigated by FISH analysis with the protocol described elsewhere .
Purification of BChE/hSA produced in vitro and in vivo
All the purification procedures were performed at 4°C unless otherwise noted. For BChE/hSA produced in vitro ~30 liters of cell media were harvested from the hollow fiber system for purification. The media were brought to 50% saturation with solid ammonium sulfate, incubated for 1 h and centrifuged at 12,000 × g for 30 min. Supernatant was collected, brought to 80% saturation with ammonium sulfate and incubated for 1 h prior to centrifugation at 12,000 × g for 30 min. The pellet was resuspended in buffer A (20 mM sodium phosphate, pH 7.4, 1 mM EDTA) and dialyzed overnight against buffer B (buffer A + 100 mM NaCl). The dialysate was loaded onto a procainamide affinity column, synthesized in house and equilibrated in buffer B. The column was washed with 10 bed volumes of buffer C (buffer A + 150 mM NaCl), and eluted with buffer D (buffer A + 300 mM NaCl). Fractions were assayed for BChE activity and those with higher-than-background BChE activity were pooled. The pool was dialyzed overnight against buffer A and stored at 4°C. For BChE/hSA purification from the milk of transgenic goats, a similar methodology was developed based on precipitation of contaminating proteins with ammonium sulfate, followed by an additional HQ50 ion exchange chromatography (Applied BioSystems, Foster City, CA) prior to the procainamide affinity column chromatography . The purity of the material was assessed by SDS-PAGE silver staining (Invitrogen) as described by the manufacturer.
For a BChE preparation with >70% tetramer, recombinant BChE produced from milk of transgenic goats was purified  and polyproline (Sigma-Aldrich) was added to the purified recombinant BChE at molar ratio of 2:1 to maximize tetramer formation. The mixture was incubated at room temperature for 2 h. Excess polyproline was removed by ultrafiltration with a 30 kDa cut-off nitrocellulose membrane. The percentage of tetramer was measured using (SEC)-HPLC .
BChE activity assay (Ellman assay), non-denaturing BChE activity gel staining, Western blot analysis and SEC-HPLC
All the procedures were described in detail previously . For SEC-HPLC protein size distribution was determined and compared with reference proteins including purified human plasma BChE (kindly provided by Dr. O. Lockridge, University of Nebraska, Omaha, NE). By using area counts, percentages of oligomeric forms of the fusion protein were determined.
Pharmacokinetic study of in vitro purified BChE/hSA
Animals were used with Guidelines on the care and use of experimental animals from CCAC. All experimental protocols were approved by the institutional animal care committee. Purified BChE/hSA fusion protein produced in vitro was injected i.v. into 2 juvenile pigs of ~20 kg (10 mg/kg, using a converting equation of 720 units = 1 mg purified plasma huBChE ). As a control, a transgenically produced recombinant BChE preparation containing more than 70% tetramer was also injected i.v. into 4 juvenile pigs at a dose of 10 mg/kg. The pigs were anesthetized with isoflurane and 30% oxygen for placement of the catheters and prior to anesthetic delivery a control blood sample was drawn. Following anesthesia a second sample was taken and the plasma used for the control BChE activity. Following injection of the various samples, blood was taken at 1, 2.5, 5, 15, 30 min then at 1 h, 2 h, 4 and 8 h from the cannulated ear vein. After 8 h the animals were allowed to awaken and further samples were taken at 24, 48, 72 and 96 h (and in some cases beyond) from the external jugular vein. Plasma was produced from the drawn blood and analyzed using the Ellman assay. The data analysis was performed by MDS Pharma Services (Montreal, QC, Canada) using NONMEM® version 5 (GloboMax, LLC, Ellicott City, MD) with a 2-compartment model.
In vitro inhibition of BChE/hSA by OP agents
Various amounts of nerve agent solutions (2–2,000 nM) were added to milk samples collected from a F1 transgenic mouse. The samples containing the fusion protein were diluted with 0.1 M Tris-HCl (pH 8.0) at × 100 fold dilutions and incubated at 25°C for 5 min. Milk collected from a negative FVB mouse and treated in a similar way served as the negative control. Residual BChE activity (%) was measured by the Ellman assay at 25°C. Data were analyzed and plotted using Microsoft Excel (Microsoft, Redmond, WA).
In vitro production and purification of BChE/hSA fusion protein
Production of the fusion protein from a selected clone, clone 35, using a hollow fiber system after transfection with the in vitro DNA expression vector, CMV/BChE/hSA, in BHK cells was initiated to generate sufficient material (~1 g in ~30 liters of media, 30 mg/liter) for purification with ammonium sulfate precipitation, followed by procainamide affinity chromatography. The purified fusion protein was analyzed by SDS-PAGE silver staining, indicating that the isolated material was ~50% pure (data not shown).
Pharmacokinetic study on BChE/hSA produced in vitro
Summary of the average (CV%) pharmacokinetic parameters from post-hoc bayesian estimates following protein i.v. injection in juvenile pigs
Form of protein
BChE/hSA produced in vitro
BChE produced transgenically (>70% tetramer)
Identification of transgenic mice and expression of the fusion protein in the milk
Summary of transgenic animals producing BChE/hSA fusion protein
Transgene copy number
Expression in milk (g/liter)*
Inhibition of BChE by OP nerve agents in vitro
Identification of transgenic goats and purification of the fusion protein in the milk
We have demonstrated that kilogram quantities of recombinant huBChE can be purified from the milk of transgenic goats where it is produced at concentrations of 1–5 g/liter and the recombinant BChE produced in the milk of transgenic goats was shown to be likely a useful bioscavenger of OP nerve agents [14, 15]. The main objective of this study was to examine if the fusion of huBChE and hSA would act in a manner to yield a novel protein that retains the recombinant BChE's binding and inhibition against OP nerve agents and the slow clearance of hSA. During the course of the study different forms of recombinant BChE/hSA were produced. To prove the concept and due to availability of materials, partially purified BChE/hSA from BHK cells was used first in the pharmacokinetic study with the purified recombinant human BChE as a control. While the purity of the fusion protein may be a concern it is difficult to envision how impurities would affect the pharmacokinetics of the protein since only the active (and hence actual) material was measured. Then transgenic mice were generated. Non-purified milk samples were obtained from a transgenic mouse and used for the nerve agent in vitro binding and inhibition assay, as it is not practical to purify recombinant proteins from milk of transgenic mice because of small volume. When the nerve agent binding and inhibition experiment was performed the only available material was from transgenic mice. There was a few years' delay from producing the fusion protein from BHK cells to obtaining the protein from transgenic goats. Nevertheless, both the pharmacokinetic study and the in vitro nerve agent binding and inhibition assay, although using different forms of the fusion protein, suggested that a novel polypeptide retaining both properties of huBChE and hSA is produced in vitro and in vivo. The production of the fusion protein in the milk of transgenic goats provided further evidence that it is possible to produce such a protein in large scale and in a cost-effective way.
Given the fact that the recombinant human BChE expressed in the milk of transgenic goats is mainly in the dimer form , it is not surprised that the major eluted fusion protein peaks from the milk of transgenic mice and goats by SEC-HPLC are dimers in size. Dimers also appeared in other hSA-fused proteins although they were only present as minor components .
(Gly)6-Ser linker was engineered to fuse the hSA with the huBChE, facilitating the probability of independent folding as well as independence of action of the two portions of the fusion protein. Although its beneficial effects remain to be explored further, similar strategies have been successfully used in generation of other functional fusion proteins, for example, heavy and light chain Ig fusion proteins  and a recombinant hirudin genetically fused to albumin .
Other efforts to improve pharmacokinetic profiles of therapeutic proteins have included addition of dextran particles and polyethylene glycol (PEG) chains to the proteins. PEGylation often improves the pharmacokinetic and toxicity profiles of a recombinant protein and it may also reduce its immunogenicity . However, high cost of PEGylation reagents and significantly reduced specific activity relative to some unmodified proteins [36, 37] are among negative factors to be considered when PEGylation is assessed. The data presented in this study as well as from other hSA-fused therapeutic proteins suggest that the disadvantages of the PEGylation can be practically overcome by fusing a therapeutic protein to hSA genetically. Clinical trials of several fusion proteins, for example, hSA fused to human growth hormone, interleukin-2 and interferon alpha, all demonstrated safety, prolonged half-life, and biological activity [17–19].
It is well known that the mammary gland of transgenic animals is a good system for recombinant protein production . A variety of recombinant human proteins, including immunoglobin, growth hormone and clotting factors, have been expressed and secreted in the milk of transgenic animals . Expression of BChE/hSA in the milk of transgenic mice and goats represents just another good example. Since the expression level of BChE/hSA was assessed based on the BChE activity the actual secretion of the total BChE/hSA protein in the milk of transgenic animals should be at least doubled as half of the fusion protein is composed of the hSA. Based on a mathematically calculated model it has been suggested that the upper limit doses of 134, 115, and 249 mg/70 kg of human plasma derived BChE are sufficient to protect RBC AChE above 30% of baseline activity following a challenge with 1 × LD50 VX, soman, and sarin, respectively, thus preventing manifestation of severe toxic signs in human . The predictions of huBChE doses were validated by in vitro experiments and data of published human studies. Therefore it is reasonable to predict that the upper limit doses described above for the plasma-derived huBChE may be doubled for the fusion protein to achieve the same protection. The experimental results presented in this study, along with other lines of evidence [14, 38], indicate that transgenic production could provide high level expression of recombinant proteins in the milk of transgenic animals with flexible scale-up and significantly lower costs and risks compared to cell culture based production systems. This technique enables the large-scale production of complex or unique molecules that may not be produced efficiently by any other systems. The present study thus provides evidence to support the conclusion that in addition to the production of recombinant huBChE in the milk of transgenic goats , sufficient quantities of BChE/hSA can be produced from transgenic goats to serve as an effective and reliable source of BChE for prophylaxis and post-exposure treatment, alternatively to the purification of plasma huBChE.
The pharmacokinetic study and the in vitro nerve agent binding and inhibition assay suggested that a huBChE/hSA fusion protein retaining both properties of huBChE and hSA is produced in vitro in BHK cells and in vivo in the milk of transgenic animals. It is possible to produce such a fusion protein in large scale and in a cost-effective way in the milk of transgenic goats.
List of abbreviations used
friend virus B-type
human serum albumin
We would like to thank Dr. O. Lockridge of Eppley Institute, University of Nebraska Medical Center for kindly providing us with purified plasma huBChE. The authors would also thank Dr. M. Tremblay and J. Penney for the generation and maintenance of transgenic mice at the Transgenic Core Facility of McGill University. We gratefully acknowledge the technical and animal health staff from PharmAthene Canada Inc. (formally Nexia Biotechnologies Inc.) for their assistance. This work was supported in part by the US Army Medical Research and Materiel Command under Contract No DAMD17-03-C-0077 and in part under a Memorandum of Understanding with Defence Research and Development Canada-Suffield.
- Lockridge O, Bartels CF, Vaughan TA, Wong CK, Norton SE, Johnson LL: Complete amino acid sequence of human serum cholinesterase. J Biol Chem. 1987, 262: 549-557.Google Scholar
- Ashani Y, Shapira S, Levy D, Wolfe AD, Doctor BP, Raveh L: Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem Pharmacol. 1991, 41: 37-41. 10.1016/0006-2952(91)90008-S.View ArticleGoogle Scholar
- Brandeis R, Raveh L, Grunwald J, Cohen E, Ashani Y: Prevention of soman-induced cognitive deficits by pretreatment with human butyrylcholinesterase in rats. Pharmacol Biochem Behav. 1993, 46: 889-896. 10.1016/0091-3057(93)90218-I.View ArticleGoogle Scholar
- Raveh L, Grunwald J, Marcus D, Papier Y, Cohen E, Ashani Y: Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem Pharmacol. 1993, 45: 2465-2474. 10.1016/0006-2952(93)90228-O.View ArticleGoogle Scholar
- Raveh L, Grauer E, Grunwald J, Cohen E, Ashani Y: The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase. Toxicol Appl Pharmacol. 1997, 145: 43-53. 10.1006/taap.1997.8160.View ArticleGoogle Scholar
- Allon N, Raveh L, Gilat E, Cohen E, Grunwald J, Ashani Y: Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase. Toxicol Sci. 1998, 43: 121-128.Google Scholar
- Lenz DE, Yeung D, Smith JR, Sweeney RE, Lumley LA, Cerasoli DM: Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. Toxicology. 2007, 233: 31-39. 10.1016/j.tox.2006.11.066.View ArticleGoogle Scholar
- Darvesh S, Hopkins DA, Geula C: Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003, 4: 131-138. 10.1038/nrn1035.View ArticleGoogle Scholar
- Ostergaard D, Viby-Mogensen J, Hanel HK, Skovgaard LT: Half-life of plasma cholinesterase. Acta Anaesthesiol Scand. 1988, 32: 266-269.View ArticleGoogle Scholar
- Bartels CF, Xie W, Miller-Lindholm AK, Schopfer LM, Lockridge O: Determination of the DNA sequences of acetylcholinesterase and butyrylcholinesterase from cat and demonstration of the existence of both in cat plasma. Biochem Pharmacol. 2000, 60: 479-487. 10.1016/S0006-2952(00)00365-8.View ArticleGoogle Scholar
- Masson P: Expression and refolding of functional human BChE from E. coli. Multidisciplinary approaches to cholinesterase functions. Edited by: Shafferman A and Velan B. 1992, New York, Plenum, 49-52.View ArticleGoogle Scholar
- Altamirano CV, Lockridge O: Association of tetramers of human butyrylcholinesterase is mediated by conserved aromatic residues of the carboxy terminus. Chem Biol Interact. 1999, 119-120: 53-60. 10.1016/S0009-2797(99)00013-7.View ArticleGoogle Scholar
- Millard CB, Lockridge O, Broomfield CA: Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase. Biochemistry. 1995, 34: 15925-15933. 10.1021/bi00049a007.View ArticleGoogle Scholar
- Huang YJ, Huang Y, Baldassarre H, Wang B, Lazaris A, Leduc M, Bilodeau AS, Bellemare A, Cote M, Herskovits P, Touati M, Turcotte C, Valeanu L, Lemee N, Wilgus H, Begin I, Bhatia B, Rao K, Neveu N, Brochu E, Pierson J, Hockley DK, Cerasoli DM, Lenz DE, Karatzas CN, Langermann S: Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc Natl Acad Sci U S A. 2007, 104: 13603-13608. 10.1073/pnas.0702756104.View ArticleGoogle Scholar
- Cerasoli DM, Griffiths EM, Doctor BP, Saxena A, Fedorko JM, Greig NH, Yu QS, Huang Y, Wilgus H, Karatzas CN, Koplovitz I, Lenz DE: In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005, 157-158: 363-365.View ArticleGoogle Scholar
- Peters T: All About Albumin: Biochemistry, Genetics, and Medical Applications. 1996, San Diego, CA, Academic PressGoogle Scholar
- Halpern W, Riccobene TA, Agostini H, Baker K, Stolow D, Gu ML, Hirsch J, Mahoney A, Carrell J, Boyd E, Grzegorzewski KJ: Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. Pharm Res. 2002, 19: 1720-1729. 10.1023/A:1020917732218.View ArticleGoogle Scholar
- Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B, Chen G, Mather D, Lin HL, Parry TJ: Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol. 2002, 456: 149-158. 10.1016/S0014-2999(02)02644-4.View ArticleGoogle Scholar
- Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C: Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther. 2002, 303: 540-548. 10.1124/jpet.102.037002.View ArticleGoogle Scholar
- Black RM, Harrison JM, Read RW: The interaction of sarin and soman with plasma proteins: the identification of a novel phosphonylation site. Arch Toxicol. 1999, 73 (2): 123-126. 10.1007/s002040050596. [http://www.springerlink.com/content/7516xcm3fuaw5enk/?p=a67fd75071ae4553853d1c4f40aa1ae4&pi=8]View ArticleGoogle Scholar
- Li B, Schopfer LM, Hinrichs SH, Masson P, Lockridge O: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay for organophosphorus toxicants bound to human albumin at Tyr411. Anal Biochem. 2007, 361: 263-272. 10.1016/j.ab.2006.11.018.View ArticleGoogle Scholar
- Peeples ES, Schopfer LM, Duysen EG, Spaulding R, Voelker T, Thompson CM, Lockridge O: Albumin, a new biomarker of organophosphorus toxicant exposure, identified by mass spectrometry. Toxicol Sci. 2005, 83: 303-312. 10.1093/toxsci/kfi023.View ArticleGoogle Scholar
- Sheffield WP, Wilson B, Eltringham-Smith LJ, Gataiance S, Bhakta V: Recombinant albumins containing additional peptide sequences smaller than barbourin retain the ability of barbourin-albumin to inhibit platelet aggregation. Thromb Haemost. 2005, 93: 914-921.Google Scholar
- Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. 1989, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, Second editionGoogle Scholar
- Arpagaus M, Kott M, Vatsis KP, Bartels CF, La Du BN, Lockridge O: Structure of the gene for human butyrylcholinesterase. Evidence for a single copy. Biochemistry. 1990, 29: 124-131. 10.1021/bi00453a015.View ArticleGoogle Scholar
- Hogan B, Beddington R, Costantini F, Lacey E: Manipulating the Mouse Embryo: A Laboratory Manual. 1986, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, First editionGoogle Scholar
- Keefer CL, Baldassarre H, Keyston R, Wang B, Bhatia B, Bilodeau AS, Zhou JF, Leduc M, Downey BR, Lazaris A, Karatzas CN: Generation of dwarf goat (Capra hircus) clones following nuclear transfer with transfected and nontransfected fetal fibroblasts and in vitro-matured oocytes. Biol Reprod. 2001, 64: 849-856. 10.1095/biolreprod64.3.849.View ArticleGoogle Scholar
- Huang YJ, Chretien N, Bilodeau AS, Zhou JF, Lazaris A, Karatzas CN: Goat uromodulin promoter directs kidney-specific expression of GFP gene in transgenic mice. BMC Biotechnol. 2005, 5: 9-10.1186/1472-6750-5-9.View ArticleGoogle Scholar
- Duysen EG, Bartels CF, Lockridge O: Wild-Type and A328W Mutant Human Butyrylcholinesterase Tetramers Expressed in Chinese Hamster Ovary Cells Have a 16-Hour Half-Life in the Circulation and Protect Mice from Cocaine Toxicity. J Pharmacol Exp Ther. 2002, 302: 751-758. 10.1124/jpet.102.033746.View ArticleGoogle Scholar
- Baldassarre H, Keefer C, Wang B, Lazaris A, Karatzas CN: Nuclear transfer in goats using in vitro matured oocytes recovered by laparoscopic ovum pick-up. Cloning Stem Cells. 2003, 5: 279-285. 10.1089/153623003772032781.View ArticleGoogle Scholar
- Cammuso C, Porter C, Nims S, Gaucher D, Melican D, Bombard S, Hawkins N, O'Coin A, Ricci C, Brayman C, Buzzell N, Ziomek C, Gavin W: Hormonal induced lactation in transgenic goats. Anim Biotechnol. 2000, 11: 1-17.View ArticleGoogle Scholar
- Muller D, Karle A, Meissburger B, Hofig I, Stork R, Kontermann RE: Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem. 2007, 282: 12650-12660. 10.1074/jbc.M700820200.View ArticleGoogle Scholar
- Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R, Oppermann H: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A. 1988, 85: 5879-5883. 10.1073/pnas.85.16.5879.View ArticleGoogle Scholar
- Syed S, Schuyler PD, Kulczycky M, Sheffield WP: Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood. 1997, 89: 3243-3252.Google Scholar
- Mahmood I, Green MD: Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet. 2005, 44: 331-347. 10.2165/00003088-200544040-00001.View ArticleGoogle Scholar
- Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M: Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem. 2001, 12: 195-202. 10.1021/bc000082g.View ArticleGoogle Scholar
- Hershfield MS, Chaffee S, Koro-Johnson L, Mary A, Smith AA, Short SA: Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc Natl Acad Sci U S A. 1991, 88: 7185-7189. 10.1073/pnas.88.16.7185.View ArticleGoogle Scholar
- Clark AJ: The mammary gland as a bioreactor: expression, processing, and production of recombinant proteins. J Mammary Gland Biol Neoplasia. 1998, 3: 337-350. 10.1023/A:1018723712996.View ArticleGoogle Scholar
- Clark J, Whitelaw B: A future for transgenic livestock. Nat Rev Genet. 2003, 4: 825-833. 10.1038/nrg1183.View ArticleGoogle Scholar
- Ashani Y, Pistinner S: Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model. Toxicol Sci. 2004, 77: 358-367. 10.1093/toxsci/kfh012. 2003/11/06View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.